CA3136447A1 - Compounds, compositions and methods - Google Patents

Compounds, compositions and methods

Info

Publication number
CA3136447A1
CA3136447A1 CA3136447A CA3136447A CA3136447A1 CA 3136447 A1 CA3136447 A1 CA 3136447A1 CA 3136447 A CA3136447 A CA 3136447A CA 3136447 A CA3136447 A CA 3136447A CA 3136447 A1 CA3136447 A1 CA 3136447A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
compound
optionally substituted
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136447A
Other languages
English (en)
French (fr)
Inventor
Javier De Vicente Fidalgo
Anthony A. ESTRADA
Jianwen A. FENG
Zachary K. Sweeney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CA3136447A1 publication Critical patent/CA3136447A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3136447A 2019-04-11 2020-04-10 Compounds, compositions and methods Pending CA3136447A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832775P 2019-04-11 2019-04-11
US62/832,775 2019-04-11
PCT/US2020/027742 WO2020210684A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
CA3136447A1 true CA3136447A1 (en) 2020-10-15

Family

ID=72752101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136447A Pending CA3136447A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Country Status (19)

Country Link
US (1) US12358896B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953348B1 (cg-RX-API-DMAC7.html)
JP (1) JP7623294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102962366B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939294A (cg-RX-API-DMAC7.html)
AR (1) AR118641A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020272045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020027A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136447A1 (cg-RX-API-DMAC7.html)
DK (1) DK3953348T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192530A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018383T3 (cg-RX-API-DMAC7.html)
IL (1) IL287120B2 (cg-RX-API-DMAC7.html)
MA (1) MA55624A (cg-RX-API-DMAC7.html)
MX (1) MX2021012392A (cg-RX-API-DMAC7.html)
SG (1) SG11202111058XA (cg-RX-API-DMAC7.html)
TW (1) TWI851710B (cg-RX-API-DMAC7.html)
WO (1) WO2020210684A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107499B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AU2021371697B2 (en) * 2020-10-29 2024-10-24 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Also Published As

Publication number Publication date
ES3018383T3 (es) 2025-05-16
EP3953348B1 (en) 2024-12-18
CN113939294A (zh) 2022-01-14
AU2020272045A1 (en) 2021-10-28
IL287120B1 (en) 2025-02-01
BR112021020027A2 (pt) 2021-12-07
TWI851710B (zh) 2024-08-11
JP7623294B2 (ja) 2025-01-28
DK3953348T3 (da) 2025-03-17
WO2020210684A1 (en) 2020-10-15
JP2022526015A (ja) 2022-05-20
AR118641A1 (es) 2021-10-20
KR102962366B1 (ko) 2026-05-11
TW202104213A (zh) 2021-02-01
AU2020272045B2 (en) 2026-01-15
EP3953348A1 (en) 2022-02-16
MX2021012392A (es) 2021-11-12
EA202192530A1 (ru) 2022-03-15
IL287120B2 (en) 2025-06-01
US20220220094A1 (en) 2022-07-14
EP3953348A4 (en) 2023-01-18
SG11202111058XA (en) 2021-11-29
ZA202107499B (en) 2022-06-29
IL287120A (en) 2021-12-01
KR20210151887A (ko) 2021-12-14
US12358896B2 (en) 2025-07-15
MA55624A (fr) 2022-02-16

Similar Documents

Publication Publication Date Title
US11840529B2 (en) Substituted pyrimidines as LRKK2 inhibitors
EP3472153B1 (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
US20220153728A1 (en) Compounds, compositions and methods
WO2017096301A1 (en) Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
CN114805361B (zh) 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
AU2020272045B2 (en) Compounds, compositions and methods
TW202231282A (zh) 稠三環類細胞週期蛋白-依賴性激酶抑制劑及其製備方法和醫藥用途
CA3253801A1 (en) N6-ADENOSINE METHYL TRANSFERASE PROTAC AND METHODS FOR USE
WO2022203984A1 (en) Vmat2 inhibitors and methods of use
HK40069073A (en) Compounds, compositions and methods
HK40069073B (en) Compounds, compositions and methods
EA050027B1 (ru) Соединения, композиции и способы
HK40074923A (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
OA19864A (en) Compounds, compositions, and methods.
HK40007576B (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
EA052777B1 (ru) Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240405

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250424

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250820

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250904

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250929

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260403

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260514